Latest filing published 18 Sept 2023 for Pyxis Oncology, Inc., €212.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Lara Sullivan: trading record in brief
This profile gathers the share dealings of Lara Sullivan in Pyxis Oncology, Inc., where the filings describe the role as chief executive. We count 11 filings; the first trade dates from 31 March 2022 and the latest from 18 September 2023.
Every open-market trade on record is a sale: 5 sales worth €76k. Outside the open market, there are 6 share grants. In 2023 alone, the filings show no purchases and 5 sales.
The newest entry dates from 18 September 2023: an open-market sale of €17k, in Pyxis Oncology, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Lara Sullivan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 100 shares@ US$2.250.5% of flowCommon StockSEC:0001209191-23-049826:0
- 20,000 shares@ US$2.270799.5% of flowCommon StockSEC:0001209191-23-049366:0
- 469,483 shares0Common StockSEC:0001209191-23-048814:0
- 703,379 shares0Common StockSEC:0001209191-23-021415:0
- 95,684 shares0Common StockSEC:0001567619-23-000068:0
- 315,273 shares0Common StockSEC:0001567619-22-008613:0
- 742,574 shares0Common StockSEC:0001140361-22-012924:0
7 of 7 declarations
